These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 24618929)

  • 1. Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy.
    Hartman J; Frishman WH
    Cardiol Rev; 2014; 22(3):147-51. PubMed ID: 24618929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights.
    Hashizume M; Tan SL; Takano J; Ohsawa K; Hasada I; Hanasaki A; Ito I; Mihara M; Nishida K
    Int Rev Immunol; 2015 May; 34(3):265-79. PubMed ID: 25099958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic uses of anti-interleukin-6 receptor antibody.
    Kang S; Tanaka T; Kishimoto T
    Int Immunol; 2015 Jan; 27(1):21-9. PubMed ID: 25142313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Humanized anti-human IL-6 receptor antibody, tocilizumab].
    Nishimoto N
    Nihon Rinsho; 2007 Jul; 65(7):1218-25. PubMed ID: 17642235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine therapy with interleukin-2/anti-interleukin-2 monoclonal antibody complexes expands CD4+CD25+Foxp3+ regulatory T cells and attenuates development and progression of atherosclerosis.
    Dinh TN; Kyaw TS; Kanellakis P; To K; Tipping P; Toh BH; Bobik A; Agrotis A
    Circulation; 2012 Sep; 126(10):1256-66. PubMed ID: 22851544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
    Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
    Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion.
    Woolley DE; Tetlow LC
    Arthritis Res; 2000; 2(1):65-74. PubMed ID: 11219391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?
    Ridker PM
    Cardiovasc Res; 2021 Sep; 117(11):e138-e140. PubMed ID: 34352102
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
    Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
    Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-6--a key mediator of systemic and local symptoms in rheumatoid arthritis.
    Cronstein BN
    Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S11-5. PubMed ID: 17708739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin 6 blockade: tocilizumab in psoriatic arthritis.
    Atzeni F; Ventura D; Batticciotto A; Boccassini L; Sarzi-Puttini P
    J Rheumatol Suppl; 2012 Jul; 89():97-9. PubMed ID: 22751605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapeutic implication of IL-6 blockade.
    Tanaka T; Kishimoto T
    Immunotherapy; 2012 Jan; 4(1):87-105. PubMed ID: 22150003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atherosclerosis: perspectives of anti-inflammatory therapy.
    Nasonov EL; Popkova TV
    Ter Arkh; 2018 May; 90(5):4-12. PubMed ID: 30701884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic targeting of the interleukin-6 receptor.
    Tanaka T; Narazaki M; Kishimoto T
    Annu Rev Pharmacol Toxicol; 2012; 52():199-219. PubMed ID: 21910626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles.
    Taleb S; Tedgui A; Mallat Z
    Arterioscler Thromb Vasc Biol; 2015 Feb; 35(2):258-64. PubMed ID: 25234818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapeutic implications of IL-6 blockade for cytokine storm.
    Tanaka T; Narazaki M; Kishimoto T
    Immunotherapy; 2016 Jul; 8(8):959-70. PubMed ID: 27381687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The biology and medical implications of interleukin-6.
    Tanaka T; Kishimoto T
    Cancer Immunol Res; 2014 Apr; 2(4):288-94. PubMed ID: 24764575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of vascular inflammation in coronary artery disease: potential of anti-inflammatory drugs in the prevention of atherothrombosis. Inflammation and anti-inflammatory drugs in coronary artery disease.
    Moreira DM; da Silva RL; Vieira JL; Fattah T; Lueneberg ME; Gottschall CA
    Am J Cardiovasc Drugs; 2015 Feb; 15(1):1-11. PubMed ID: 25369900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy.
    Tanaka T; Narazaki M; Ogata A; Kishimoto T
    Semin Immunol; 2014 Feb; 26(1):88-96. PubMed ID: 24594001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Examining the Role of and Treatment Directed at IL-1β in Atherosclerosis.
    Khan R; Rheaume E; Tardif JC
    Curr Atheroscler Rep; 2018 Sep; 20(11):53. PubMed ID: 30219977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.